Department of Dermatology and Allergy, University Hospital Bonn, Venusberg Campus 1, Bonn, Germany; Christine Kühne-Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.
Innovaderm Research, Montréal, QC, Canada.
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1473-1486.e2. doi: 10.1016/j.jaip.2021.02.027.
Severity of atopic dermatitis (AD) correlates with impact on health-related quality of life (HRQoL), work productivity, and burden on health systems. Tools to measure severity inform regulatory approval, drug access, and value- or measurement-based care. A core set of instruments for measuring AD has been established. Clinician-reported tools are divided broadly into multi-item global estimates or precise calculators that also weigh affected corporeal surfaces. Increasingly, subjective patient-reported outcomes are valued, with the potential to capture vast amounts of health-related data. Patient-reported outcomes can be disease-agnostic, skin-related, or AD-specific, and evaluate global disease, itch severity, long-term control, or overall HRQoL. Patient-reported outcomes are expansive in number; therefore, item banks and adaptive digital user interfaces will be increasingly needed, along with capacity to store and analyze data. Technologies for AD include tools for communication, severity assessment, or data exchange, as well as electronic health records (EHRs). For clinicians, a limited number of applications exist, with relatively poor interoperability with EHRs to date. For patients, a growing number of mobile health (mHealth) applications exhibit variable compliance with international guidelines for self-management. Data privacy and information security governance are key considerations in the development of information technologies for AD. Integrated and streamlined digital operational processes for disease measurements may build capacity for high value and efficient care of patients with AD across the globe.
特应性皮炎（AD）的严重程度与健康相关生活质量（HRQoL）、工作生产力以及对卫生系统的负担有关。用于衡量严重程度的工具可提供监管审批、药物获取和基于价值或基于测量的护理信息。已经建立了一套用于衡量 AD 的核心工具集。临床医生报告的工具大致可分为多项目全球估计或精确计算器，这些工具还可以衡量受影响的身体表面。越来越重视主观的患者报告结果，有可能捕获大量的与健康相关的数据。患者报告结果可以是与疾病无关的、与皮肤相关的或 AD 特异性的，评估总体疾病、瘙痒严重程度、长期控制或总体 HRQoL。患者报告结果数量众多；因此，将越来越需要项目库和自适应数字用户界面，以及存储和分析数据的能力。AD 的技术包括用于沟通、严重程度评估或数据交换的工具，以及电子健康记录（EHR）。对于临床医生，目前只有少数应用程序存在，并且迄今为止与 EHR 的互操作性相对较差。对于患者，越来越多的移动健康（mHealth）应用程序在自我管理的国际指南方面表现出不同的合规性。在开发 AD 的信息技术时，数据隐私和信息安全治理是关键考虑因素。用于疾病测量的集成和简化的数字化操作流程可能会提高全球 AD 患者的高价值和高效护理能力。
